BeiGene said its four-target natural killer cell therapy collaboration with Shoreline Biosciences is over. And by reneging on Shoreline’s iPSC-NK cell technology, BeiGene loses its “entry into cell therapy,” a phrase used to describe the tie-up in an investor presentation last year.
SAN DIEGO, Aug. 3, 2023 /PRNewswire/ -- Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing effective and differentiated cellular immunotherapies based on induced pluripotent stem cells (iPSCs) derived natural killer cells (iNK) and macrophages (iMACs), today announced that it will participate in the 2023 Wedbush Pacgrow Healthcare Conference taking place August 8-9, 2023 in New York, NY.
Shoreline Biosciences, Inc., a biopharmaceutical company developing next-generation cellular immunotherapies, announced the appointment of Mauro Avanzi, chief medical officer.
Editas Medicine will sell its cancer cell therapy work to privately held Shoreline Biosciences as part of a company-wide restructuring that’s already led to layoffs and cutbacks in spending.
SAN DIEGO, May 10, 2022 /PRNewswire/ -- Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its proprietary iPSC-derived natural killer (iNK) cell and macrophage (iMACs) platforms, today announced that it will present two posters at the 19th Meeting of the Society for Natural Immunity (NK2022), taking place May 14 – 17, 2022 at the Hyatt Coconut Point in Bonita Springs, Florida. Shoreline will present two posters demonstrating its novel methodologies to produce iNK cells.
Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of cellular immunotherapy, and Shoreline Biosciences, a biotechnology company developing allogeneic off-the-shelf, standardized, and targeted natural killer (NK) and macrophage cellular immunotherapies derived from induced pluripotent stem cells (iPSC) for cancer, have formed an alliance to advance the future of iPSC-derived cellular therapies.